PD-L1-specific T cells

Shamaila Munir Ahmad; Troels Holz Borch; Morten Hansen; Mads Hald Andersen

doi:10.1007/s00262-015-1783-4

PD-L1-specific T cells

Shamaila Munir Ahmad, Troels Holz Borch, Morten Hansen, Mads Hald Andersen^*

^*Corresponding author for this work

Glycomics Program

12 Citations (Scopus)

Abstract

Recently, there has been an increased focus on the immune checkpoint protein PD-1 and its ligand PD-L1 due to the discovery that blocking the PD-1/PD-L1 pathway with monoclonal antibodies elicits striking clinical results in many different malignancies. We have described naturally occurring PD-L1-specific T cells that recognize both PD-L1-expressing immune cells and malignant cells. Thus, PD-L1-specific T cells have the ability to modulate adaptive immune reactions by reacting to regulatory cells. Thus, utilization of PD-L1-derived T cell epitopes may represent an attractive vaccination strategy for targeting the tumor microenvironment and for boosting the clinical effects of additional anticancer immunotherapy. This review summarizes present information about PD-L1 as a T cell antigen, depicts the initial findings about the function of PD-L1-specific T cells in the adjustment of immune responses, and discusses future opportunities.

Original language	English
Journal	Cancer Immunology, Immunotherapy
Volume	65
Issue number	7
Pages (from-to)	797-804
Number of pages	8
ISSN	0340-7004
DOIs	https://doi.org/10.1007/s00262-015-1783-4
Publication status	Published - Jul 2016

Keywords

Anti-Tregs
Cancer vaccines
CITIM 2015
PD-L1
PD-L1-specific T cells

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00262-015-1783-4

Cite this

@article{90b484765bbd4f80b836b94ba5c92128,

title = "PD-L1-specific T cells",

abstract = "Recently, there has been an increased focus on the immune checkpoint protein PD-1 and its ligand PD-L1 due to the discovery that blocking the PD-1/PD-L1 pathway with monoclonal antibodies elicits striking clinical results in many different malignancies. We have described naturally occurring PD-L1-specific T cells that recognize both PD-L1-expressing immune cells and malignant cells. Thus, PD-L1-specific T cells have the ability to modulate adaptive immune reactions by reacting to regulatory cells. Thus, utilization of PD-L1-derived T cell epitopes may represent an attractive vaccination strategy for targeting the tumor microenvironment and for boosting the clinical effects of additional anticancer immunotherapy. This review summarizes present information about PD-L1 as a T cell antigen, depicts the initial findings about the function of PD-L1-specific T cells in the adjustment of immune responses, and discusses future opportunities.",

keywords = "Anti-Tregs, Cancer vaccines, CITIM 2015, PD-L1, PD-L1-specific T cells",

author = "Ahmad, {Shamaila Munir} and Borch, {Troels Holz} and Morten Hansen and Andersen, {Mads Hald}",

year = "2016",

month = jul,

doi = "10.1007/s00262-015-1783-4",

language = "English",

volume = "65",

pages = "797--804",

journal = "Cancer Immunology, Immunotherapy",

issn = "0340-7004",

publisher = "Springer",

number = "7",

}

TY - JOUR

T1 - PD-L1-specific T cells

AU - Ahmad, Shamaila Munir

AU - Borch, Troels Holz

AU - Hansen, Morten

AU - Andersen, Mads Hald

PY - 2016/7

Y1 - 2016/7

N2 - Recently, there has been an increased focus on the immune checkpoint protein PD-1 and its ligand PD-L1 due to the discovery that blocking the PD-1/PD-L1 pathway with monoclonal antibodies elicits striking clinical results in many different malignancies. We have described naturally occurring PD-L1-specific T cells that recognize both PD-L1-expressing immune cells and malignant cells. Thus, PD-L1-specific T cells have the ability to modulate adaptive immune reactions by reacting to regulatory cells. Thus, utilization of PD-L1-derived T cell epitopes may represent an attractive vaccination strategy for targeting the tumor microenvironment and for boosting the clinical effects of additional anticancer immunotherapy. This review summarizes present information about PD-L1 as a T cell antigen, depicts the initial findings about the function of PD-L1-specific T cells in the adjustment of immune responses, and discusses future opportunities.

AB - Recently, there has been an increased focus on the immune checkpoint protein PD-1 and its ligand PD-L1 due to the discovery that blocking the PD-1/PD-L1 pathway with monoclonal antibodies elicits striking clinical results in many different malignancies. We have described naturally occurring PD-L1-specific T cells that recognize both PD-L1-expressing immune cells and malignant cells. Thus, PD-L1-specific T cells have the ability to modulate adaptive immune reactions by reacting to regulatory cells. Thus, utilization of PD-L1-derived T cell epitopes may represent an attractive vaccination strategy for targeting the tumor microenvironment and for boosting the clinical effects of additional anticancer immunotherapy. This review summarizes present information about PD-L1 as a T cell antigen, depicts the initial findings about the function of PD-L1-specific T cells in the adjustment of immune responses, and discusses future opportunities.

KW - Anti-Tregs

KW - Cancer vaccines

KW - CITIM 2015

KW - PD-L1

KW - PD-L1-specific T cells

U2 - 10.1007/s00262-015-1783-4

DO - 10.1007/s00262-015-1783-4

M3 - Review

C2 - 26724936

AN - SCOPUS:84952646591

SN - 0340-7004

VL - 65

SP - 797

EP - 804

JO - Cancer Immunology, Immunotherapy

JF - Cancer Immunology, Immunotherapy

IS - 7

ER -

PD-L1-specific T cells

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this